Bile duct cancer is a rare but highly aggressive bile duct cancer, representing one of the most challenging combats in the fight against cancer. This invisible disease is usually not discovered, until it reaches the advanced stage, it is difficult to treat and lead to poor prognosis of many patients. With the further exploration of the complex environments around these tumors, bile duct cancer is allowed to reproduce and hide the hiding of drug treatment. The core of this discovery is a kind of protein that can hold new and more effective themes.
Researchers at the Albany Medical College, led by Professor Paul Higgins, and doctorate with Dr. Ralf-Peter CZEKAY, Hasan Aydin (Hasan Aydin) Dr. Rohan Samarakoon, Dr. Rohan Samarakoon, Dr. Nusret Subasi, Dr. Hwajeong Lee, Craig Higgins and Stephen Higgins (Stephen Higgins) ) The current data provides a key opinion on the role of Serpine1 in the progress of the progress of cholecusal cancer (CCA). Their research was published in cells, clarifying how the tumor microe environmental (TME) in CCA was shaped by cancer -related fibroblasts (CAF), and how this drove tumor progress and resistance to treatment.
Researchers emphasized that the dehydration reaction (the process of denseness around the tumor, the process of accumulation of fibrosis) is a key factor in prognosis in bile duct cancer and the resistance to chemotherapy resistance. In this fibrosis environment, CAFS plays a core role by reshaping the extracellular matrix (ECM), promoting the survival of tumor cells and promoting the growth and diffusion of cancer.
Serpine1 is a gene that encodes a complain iconic activation agent 1 (PAI-1), which is identified as an important participant in this process. The study showed that PAI-1 participated in the ECM reshape in large quantities, thereby enhancing the fibrous nature of TME. PAI-1 not only supports the physical structure of the surrounding environment of the tumor, but also helps cancer cells, metastasis and resistance to cell death. Higgins explained when discussing these discussions: “The multi-functional role of PAI-1 in the progress of CCA makes it a potential treatment target, especially considering its aggression and resistance to these tumors Contribution “”
The team explores complex signaling pathways that promote interaction between CAF and tumor cells. The TGF-β path, especially through the interaction with Serpine1, is prominently displayed as the main driving force for the desalination reaction in the CCA. This path not only enhances the fibrosis environment, but also promotes the dryness and plasticity of cancer cells, making it more adaptable and resistant to therapy.
In order to destroy this harmful interaction, the study shows that the target for PAI-1 or related channels may be beneficial. The low experimental knock in PAI-1 in the cholecolic cancer cells causes a significant decrease in cell movement, indicating that inhibitory PAI-1 may slow down or prevent the spread of cancer. Higkins added: “Our discovery shows that PAI-1 targeted in the micro-environment of tumor can provide a new treatment method for treating bile duct cancer, especially when the tumor is resistant to conventional therapy.”
This study by Professor Higgins and his colleagues not only enhances our understanding of the molecular mechanism of driving cholangion cancer, but also has opened a new way for treatment intervention. Through TME components that promote tumor growth and resistance, their work has improved prognosis for patients with challenging diseases.
Journal reference
CZEKAY, R.-P., Higgins, CE, Aydin, HB, Samarakoon, R., Subasi, NB, Higgins, SP, Lee, H. , & Higgins, PJ (2024). “Serpine1: The role in the progress of bile duct cancer and the treatment target in the micro -micro -environment.” Cells, 13,796. Doi: https: //doi.org/10.3390/cells13100796
About the author
Paul J. Higgins (Paul J. Higgins) He received his doctorate degree in 1976, and New York University obtained molecular biology degrees. Essence Dr. Higgins is currently a professor and chairman of the Department of Biology of Cancer Cell Biology at the Olbani Olbani Olbani Olbani Medical College in New York. He is the founding vice president of the Olbani Institute (ARI) and is currently a member of the ARI board. He has served as the chairman of the National Institute of Health and the Ministry of National Defense. He is a member of many federal and international research departments, and has won several awards with high reputation, including MOYER Award and the 2008 Molecular Medical Excellence Award. Dr. Higgins is a member of several journal editorial committees. He edited books about cancer biology and published more than 300 scientific papers for peer review.
Ralph Peter Czech Republic He received his doctorate degree in 1991, MAX-PLANCK-Instute molecular physiology degree in Dortmund in Germany. Essence Marilyn Farquhar and David Loskutoff. During this period, Dr. CZEKAY attributed to type 1 of the latchase inhibitors in the morraine protease inhibitors. Tumor progress, especially when they drive tumor progress. At that time, several research teams emphasized the results of unexpected clinical observations, that is, the expression of elevation of PAI-1 was accidentally manifested as a strong symbol with poor prognosis of breast cancer and a shorter survival period. Through his own research, he described a new mechanism that supports this concept. Among them, PAI-1 regulates the activity of integrated activity (the activity of a class of cell adhesion molecules) Cell movement. In 2004, Dr. CZEKAY joined the faculty and staff of the Department of Regeneration and Cancer Biology at the Olbani Medical College in Olbani, New York. He started and continued to expand the PAI-1 function to the prostate and ovarian cancer model. At present, he is forming a comprehensive interdisciplinary research team with his colleague Paul Higgins and members of the Department of Pathology and Medicine of AMC. 1 New treatment method of function. Dr. CZEKAY published his research in scientific journals reviewed by his peer and introduced it at many countries and international science conferences.
Hasan Basri Aydin (Hasan Basri Aydin) He graduated from the CerrahpaSa School of Medicine at the University of Istanbul in 2017, where he had a strong interest in pathology. After working briefly in Turkey, Dr. Aidin moved to the United States and started pathological training at the Olbani Medical Center in 2021, focusing on gastrointestinal tract, liver and pancreas cortical pathology. This focus has led him to accept the gastrointestinal pathological research gold of Northwell Health. Dr. Aydin’s research interest made him contribute many publications to the benign and vicious conditions of the digestive tumor and the benign and vicious conditions of the liver and pancreas. Dr. Aydin is a member of the New York Society (NYPS), Rodger C. Haggitt Society (GIPS), Hans Popper Hepatopatology Society, and Pancreatobilily Pathology. He has participated in the National Pathological Conference as a host, including USCAP, ASCP and CAP annual conference. Dr. Aydin’s latest manuscript was titled “Gastric cancer was used as a metastatic AFP for hepatocytal carcinoma in the liver biopsy” and was published as the GIPS case in July 2024.
Hwajeong lee It is a professor of pathology and laboratory medical professors in the Department of Medicine and Pathology of Olbani Olbani Medical College, New York, and vice chairman of academic affairs. She completed medical education at the Yonsei School of Medicine, Seoul, South Korea, and at the Henry Ford Hospital at Detroit in Detroit’s Henry Ford Hospital at Detroit, respectively. To. Her research interest is concentrated in identification to help diagnosis, prognosis and treatment of gastrointestinal tract, the morphology of variable tumors and non -tumor diseases and immunohistochemicals of gastrointestinal tract, liver and pancreas.
NUSRET BEKIR SUBASI It is a graduate year-1 pathological resident, living in the Olbani Medical Center in Olbani, New York. After Dr. Subasi graduated from Gaziantep University of Turkey in 2018, he had various clinical and research experience in pathology before his current position. He is full of enthusiasm for possible future translation and collaborative research projects.
